Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First, is scheduled to end on July 31st. Learn about your options to continue receiving care at Temple Health.
Fox Chase Cancer Center and Fox Chase – Temple Urologic Institute Cut Ribbon on Redesigned Clinical Space
PHILADELPHIA (May 17, 2024) — Fox Chase Cancer Center and the Fox Chase - Temple Urologic Institute are proud to welcome patients to the newly renovated and expanded clinical space located on the third floor of Fox Chase - Huntingdon Pike, which is located at 50 Huntingdon Pike in Rockledge, Pennsylvania. These renovations are aimed at significantly improving care for urology and urologic oncology patients both within the region and beyond.
“With this transformation of our clinical space we are poised to offer easier access to top-of-the-line, innovative care for our patients. We are thrilled to have completed this exciting renovation and look forward to the continued growth of the Fox Chase - Temple Urologic Institute,” said Robert Uzzo, MD, MBA, FACS, President and CEO of Fox Chase and Executive Director of the Urologic Institute.
“Our team of urologists have been at the forefront of utilizing innovative treatment methods to provide better options for patients,” said Alexander Kutikov, MD, FACS, Chair of the Department of Urology at Fox Chase. “This expansion of clinical space will allow us to continue to provide that high level of transformative care by not only increasing the number of patients we can see on a daily basis, but by providing them with a more streamlined treatment experience.”
Over the past 10 years, Fox Chase - Huntingdon Pike has seen a 122% increase in the number of patient visits and a 157% increase in the number of procedures performed. Since moving to this location in 2008, the Department of Urology and the Urologic Institute, which launched last year, have grown from four urology attending physicians and three physician assistants to 12 attending physicians and seven physician assistants.
The Urologic Institute is designed to provide a seamless transition for patients with urologic cancers who require treatment for benign urology conditions following cancer therapy. It offers patients cutting-edge clinical trials, targeted therapies, immunotherapies, and advanced radiation therapies for the treatment of urologic cancers, including prostate, kidney, bladder, adrenal, testicular, penile, ureteral, and urethral. Its urologic oncologists collaborate closely with renowned medical and radiation oncologists to take a multidisciplinary approach to treating cancer, including diagnosis, treatment, and follow-up care.
Urologists at Fox Chase - Huntingdon Pike were among the first in the region to implement enhanced diagnostic technologies, including MRI-U/S fusion, micro-ultrasound, and, most recently, office-based transperineal prostate biopsy, further underscoring their commitment to providing cutting-edge urologic care.
Additionally, the urology team at Fox Chase - Huntingdon Pike operates one of the busiest intravesical bladder cancer therapy clinics in the country. It also plays a pivotal role in assisting Philadelphia patients in navigating through shortages of Bacillus Calmette-Guérin (BCG) therapy and offers the latest intravesical treatments such as gemcitabine and docetaxel.
Furthermore, in addition to intrarenal BCG therapy, Fox Chase - Huntingdon Pike is proud to be the first in the region to provide patients access to nadofaragene firadenovec, which is also known by its brand name Adstiladrin, marking a significant advancement in its intravesical therapy capabilities. Adstiladrin is a newer gene therapy used to treat adult patients with bladder cancer that is unresponsive to BCG therapy.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427